logo

ATXS

Astria Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
consensus rating "Buy"
EPS Beats Expectation

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About ATXS

Astria Therapeutics, Inc.

A company that develops novel therapeutics for the rare and niche allergic and immunological diseases

Pharmaceutical
06/26/2008
06/25/2015
NASDAQ Stock Exchange
78
12-31
Common stock
75 State Street, Suite 1400, Boston, Massachusetts 02109
--
Astria Therapeutics, Inc., was founded in Delaware on June 26, 2008 and is headquartered in Cambridge, Massachusetts. The company is a biopharmaceutical company focused on the discovery, development and commercialization of new therapies. The company's mission is to bring hope to patients and families affected by rare and niche allergic and immune diseases through life-changing therapies. The company's lead product candidate is STAR-0215, a potentially best-in-class monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. Based on the data generated so far and the existing HAE treatment profile, STAR-0215 has the potential to be the most patient-friendly chronic treatment for HAE.

Company Financials

EPS

ATXS has released its 2024 Q4 earnings. EPS was reported at -0.44, versus the expected -0.43, missing expectations. The chart below visualizes how ATXS has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime